Greifswald: With an investment of approximately 340 million euros, CHEPLAPHARM Arzneimittel GmbH breaks all private sector records in Mecklenburg-Western Pomerania and moves into the big league for medium-sized pharmaceutical companies in Germany.
The investments went predominantly into the worldwide rights for established brands such as the anti-obesity drug XENICAL® and the beta blocker DILATREND®. Negotiations with the Basel pharmaceutical company F. Hoffmann-La Roche Ltd. started at the beginning of the year. The agreements were signed at the end of September and immediately executed for XENICAL® on 30 September 2016. Closing for DILATREND® will likely take place in early January 2017.
“We have already made major investments in the past, but this deal will be a crucial and pioneering milestone in our company history,” says the Management.
The smaller investment portion will go into site expansion in Greifswald. Management is proud to announce: “We expect this investment to result in record sales of 240 million euros for next year. That constitutes a growth rate of 108 percent. It will make us one of the fastest growing medium-sized pharmaceutical companies in Germany.”
Business was already flourishing for CHEPLAPHARM back in 2015. Three-digit million amount were invested in new product rights in order to exceed the limit of 100 million euros in annual sales. This resulted in numerous newly created jobs. “We have now more than of 100 employees and are very happy that the new projects will provide for a total of 50 new employees – of which 90 percent are graduates – and offering a sustainable career. This is unfortunately rather unusual in the MV region,” says the Management.
CHEPLAPHARM has further goals: “By proactively anticipating future trends and with the help of our young, highly trained team, we aim to be among the top five medium-sized pharmaceutical companies.” The projects were financed by a bank group and the capital market rather than by subsidies. CHEPLAPHARM is primarily known on the international pharmaceutical market as a niche product supplier. Leveraging a Buy-And-Build strategy, CHEPLAPHARM generates double-digit annual growth rates and is the newcomer to the medium-sized German pharmaceutical sector.
Press office:
CHEPLAPHARM Arzneimittel GmbH | Ziegelhof 24 | 17489 Greifswald | presse(at)cheplapharm.com